197 related articles for article (PubMed ID: 33764261)
1. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
Kim JH; Ahn DH; Moon JS; Han HJ; Bae K; Yoon KA
Vet Q; 2021 Dec; 41(1):153-162. PubMed ID: 33764261
[TBL] [Abstract][Full Text] [Related]
2. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955
[TBL] [Abstract][Full Text] [Related]
6. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs.
Yamasaki H; Uematsu Y; Hayashi Y; Yamashita M; Tei M; Uchida K; Ono K; Hirao H
Can J Vet Res; 2022 Oct; 86(4):286-293. PubMed ID: 36211215
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
[TBL] [Abstract][Full Text] [Related]
8. BRAF
Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
[TBL] [Abstract][Full Text] [Related]
9. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
10. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
Mochizuki H; Breen M
Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
[TBL] [Abstract][Full Text] [Related]
11. Recurrent and metastatic canine urethral transitional cell carcinoma without bladder involvement.
Santos M; Dias Pereira P; Montenegro L; Faustino AM
Vet Rec; 2007 Apr; 160(16):557-8. PubMed ID: 17449714
[No Abstract] [Full Text] [Related]
12. Aberrant expression of the COX2/PGE
Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
[TBL] [Abstract][Full Text] [Related]
14. Metastatic transitional cell carcinoma in proximal humerus of a dog.
Malek S; Murphy KA; Nykamp SG; Allavena R
Can Vet J; 2011 Sep; 52(9):1013-7. PubMed ID: 22379204
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
16. Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog.
Butty EM; Hahn S; Labato MA
J Vet Intern Med; 2021 May; 35(3):1551-1557. PubMed ID: 33739477
[TBL] [Abstract][Full Text] [Related]
17. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma.
Mochizuki H; Shapiro SG; Breen M
PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430
[TBL] [Abstract][Full Text] [Related]
18. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA
BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
